Concepedia

Salvage Chemotherapy in Recurrent Platinum-Resistant or Refractory Epithelial Ovarian Cancer with Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox<sup>®</sup>)

Nipon Khemapech, Shina Oranratanaphan, Wichai Termrungruanglert, Ruangsak Lertkhachonsuk, A. Vasurattana

Asian Pacific Journal of Cancer Prevention · 2013 · 19 citations · 32 references

DOIFull text

Open access

Abstract

DPLD, the second-generation PLD drug combined with carboplatin every 4 weeks, is effective and has low toxicity for treatment of patients with recurrent platinum-resistant or refractory epithelial ovarian cancer.

References

32

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

William P. McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine · 1996 · 2.9K citations · Full text

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

Demetrios Papahadjopoulos, Theresa M. Allen, Alberto Gabizón et al. · Proceedings of the National Academy of Sciences · 1991 · 1.6K citations

, , +15

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

Alberto Gabizón, Raphael Catane, Beatrice Uziely et al. · PubMed · 1994 · 1.4K citations

, , +22

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Alberto Gabizón, Demetrios Papahadjopoulos · Proceedings of the National Academy of Sciences · 1988 · 1.1K citations · Full text

, , +16